Search the Newsreel

Clinical: FDA Accelerates Allogene's TALEN-Edited Lymphoma Cell Therapy

The FDA has granted RMAT and Fast Track designations to Allogene's TALEN-edited, allogeneic CD19 CAR T-cell therapy, cema-cel, for first-line consolidation in large B-cell lymphoma. An interim analysis showed cema-cel cleared minimal residual disease in a significant proportion of patients, with no serious adverse …

Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs

Allogene Therapeutics (ALLO) reported a narrower-than-expected Q2 2026 loss of 13 cents per share, beating the Zacks Consensus Estimate of 16 cents, primarily due to lower research and development costs. The company's cash position extended its runway into 2029, and it is progressing with …

Allogene Therapeutics Remains Attractive Given Valuation, Clinical Strategy, RBC Says

RBC Capital Markets reiterated that Allogene Therapeutics remains an attractive investment due to its appealing valuation and distinctive clinical strategy. The company highlighted a 41% improvement in minimal residual disease on the large B-cell lymphoma front. Access to the full analysis requires a premium …

Allogene Therapeutics, Inc. Announces Cemacabtagene Ansegedleucel (Cema-Cel) Is Being Evaluated in Alpha3, the First Pivotal, Randomized Phase 2 Trial in LBCL

Allogene Therapeutics announced that cemacabtagene ansegedleucel (cema-cel) is being evaluated in ALPHA3, a pivotal Phase 2 trial for high-risk Large B-Cell Lymphoma (LBCL) patients. The trial aims to assess if MRD-guided treatment can delay or prevent relapse, with early data showing favorable MRD negativity …

722,928 Shares in Allogene Therapeutics, Inc. $ALLO Acquired by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. has acquired a new position of 722,928 shares in Allogene Therapeutics, Inc. (NASDAQ:ALLO), valued at approximately $1.5 million. This purchase gives the firm a 0.21% stake in the company, contributing to the 83.63% institutional ownership of Allogene. The …

Allogene Therapeutics (ALLO) Advances Clinical Pipeline Amidst H

Earnings call transcript: Allogene Therapeutics beats Q2 2026 EPS forecast

Allogene Therapeutics reported a narrower-than-expected loss for Q2 2026, with adjusted EPS of negative $0.13 against a forecast of negative $0.17. Revenue significantly surpassed expectations, driven primarily by clinical advancements rather than financial metrics. The company's ALPHA3 trial in large B-cell lymphoma is progressing …

Allogene Therapeutics earnings beat by $0.04, revenue topped estimates

Allogene Therapeutics (NASDAQ: ALLO) reported better-than-expected earnings for the second quarter, beating analyst EPS estimates by $0.04 and significantly exceeding revenue forecasts. The company posted an EPS of $-0.130 on revenue of $4.64M. The stock has shown strong performance, rising 2.750% in the last …

Allogene Therapeutics (NASDAQ:ALLO) Issues Earnings Results, Beats Estimates By $0.04 EPS

Earnings Flash (ALLO) Allogene Therapeutics Posts Q2 Loss $0.13 per Share, vs. FactSet Est of $0.17 Loss

Allogene Therapeutics: Q2 Earnings Snapshot

Allogene Therapeutics Inc. reported a Q2 loss of $42.7 million, or 13 cents per share, surpassing Wall Street expectations which had forecast a loss of 16 cents per share. The immuno-oncology company generated $4.5 million in revenue for the period. Shares of Allogene Therapeutics …

Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update

Allogene Therapeutics reported its second-quarter 2026 financial results, highlighting significant progress in its ALPHA3 program for cema-cel in 1L Large B-cell Lymphoma, which received RMAT and Fast Track designations from the FDA. The company also provided an update on its Phase 1 RESOLUTION trial …

Allogene Therapeutics Inc (ALLO) Q2 2026 Earnings Report Preview: What To Look For

Allogene Therapeutics, Inc. expected to post a loss of 17 cents a share - Earnings Preview

Allogene Therapeutics, Inc. is projected to report a loss of 17 cents per share. This information comes from an earnings preview, indicating an anticipated financial performance for the company. The full article provides more details, accessible through a TradingView subscription.

Allogene Therapeutics (ALLO) stake: Belldegrun group reports 3.9% ownership

Dr. Arie Belldegrun and affiliated entities have filed an amended passive ownership report for Allogene Therapeutics (ALLO), disclosing a beneficial ownership of 13,610,578 shares, which represents 3.9% of the outstanding common stock as of May 11, 2026. This total includes shares from stock options …

State Street Corporation (ALLO) discloses 5.5% beneficial stake in Allogene

State Street Corporation has disclosed a 5.5% beneficial ownership stake in Allogene Therapeutics, Inc., holding 19,025,826 shares of common stock. The filing, a Schedule 13G, indicates that State Street exercises shared voting power over 18,772,433 shares and shared dispositive power over all 19,025,826 shares, …

Allogene Therapeutics (ALLO) Expected to Release Quarterly Earnings on Wednesday

Allogene Therapeutics Q2 Results: Earnings Call Set for Aug 12

Allogene Therapeutics will report its Q2 2026 financial results and provide a business update on August 12, 2026, after market close, followed by a webcast and conference call at 2:00 p.m. PT/5:00 p.m. ET. The company, a clinical-stage biotechnology firm, focuses on developing allogeneic …

Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update

Allogene Therapeutics announced it will report its second quarter 2026 financial results and provide a business update on August 12, 2026, after market close. This will be followed by a live audio webcast and conference call at 2:00 p.m. PT/5:00 p.m. ET. The company, …

Allogene sets Aug. 12 update on cancer and autoimmune disease

Allogene Therapeutics (NASDAQ: ALLO) announced it will report its second-quarter 2026 financial results and provide a business update on August 12, 2026, after the market close. The company will host a live audio webcast and conference call at 2:00 p.m. PT / 5:00 p.m. …

Allogene Therapeutics Inc (ALLO) Risk Assessment: Volatility, Financial Risk & Investment Risk

Allogene Therapeutics Inc (ALLO) has a current risk assessment score of 3.70, placing it 115th out of 384 companies in the Biotechnology & Medical Research industry. The company's beta value of 0.47 indicates lower volatility compared to the S&P 500. The report details various …

FDA Grants RMAT, Fast Track Status To Cema-cel For High-Risk Large B-cell Lymphoma; Stock Up

(RTTNews) - Allogene Therapeutics, Inc. (ALLO), a clinical-stage biotechnology company, announced that the U.S. FDA has granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track Designations to cemacabtagene ansegedleucel, or cema-cel, in Large B-Cell Lymphoma, supported by data from the Phase 2 ALPHA 3 …

Allogene rises as FDA offers Fast Track, RMAT tags to cell therapy

Shares of Allogene Therapeutics (ALLO [https://seekingalpha.com/symbol/ALLO]) rose on Wednesday after the U.S. Food and Drug Administration awarded the Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations for the company’s cell therapy candidate cema-cel. Also known as cemacabtagene ansegedleucel, the allogeneic CAR T product …

Allogene Therapeutics, Inc. Receives FDA Regenerative Medicine Advanced Therapy And Fast Track Designations For Cemacabtagene Ansegedleucel As First-Line Consolidation Therapy For Large B-Cell Lymphoma

Allogene Therapeutics has received both Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the FDA for its investigational CAR T product, cemacabtagene ansegedleucel (cema-cel). These designations are for cema-cel as a first-line consolidation therapy for adult patients with high-risk large B-cell lymphoma …

Allogene Therapeutics stock rises on FDA regulatory designations

Allogene Therapeutics Inc. (NASDAQ:ALLO) shares increased after the FDA granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations to its experimental therapy cema-cel. These designations are for treating adult patients with large B-cell lymphoma (LBCL) who test positive for minimal residual disease (MRD) …

Allogene Reports No Minimal Residual Disease in 7 of 12 Cema-Cel Patients

Allogene Therapeutics announced that the U.S. FDA has granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations to its investigational allogeneic CAR T therapy cemacabtagene ansegedleucel (cema-cel). These designations are based on interim data from the pivotal ALPHA3 trial, where 58.3% of cema-cel-treated …

Insider Sellers Might Regret Selling Allogene Therapeutics Shares at a Lower Price Than Current Market Value

Insiders at Allogene Therapeutics sold US$603k worth of shares over the past year at an average price of US$1.85, which is lower than the current share price. This suggests that these sellers might now regret their decision given the stock's recent price movements, despite …

Allogene Therapeutics Inc (ALLO) Financial Health: Profitability & Balance Sheet Analysis

The article provides an analysis of Allogene Therapeutics Inc (ALLO)'s financial health, noting its current financial score of 5.10 and a ranking of 377 out of 385 in the Biotechnology & Medical Research industry, indicating a weak financial status and low operating efficiency. Key …

Allogene Therapeutics, Inc. Stock 12‑Month Price Target Cut to $8.75, Implies 381% Upside

Allogene Therapeutics, Inc.'s average 12-month stock price target has been lowered to $8.75 from $9 by 8 analysts, with forecasts ranging from $4 to $14 per share. This new target suggests a potential upside of approximately 381% based on the July 23 closing price. …

Allogene Therapeutics Inc (ALLO) Cash Flow

This article provides a detailed cash flow statement for Allogene Therapeutics Inc (ALLO) on a quarterly and annual basis. It breaks down operating, investing, and financing cash flows, including specific line items such as net income from continuing operations, capital expenditures, and changes in …

Allogene Therapeutics Inc (ALLO) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Allogene Therapeutics Inc (ALLO)'s dividend history and stock splits. It states that the company has distributed $0.00 in dividends over the past five years and currently has no dividend data available. The content primarily focuses on the company's …

Allogene Therapeutics, Inc. Revenue Breakdown – NASDAQ:ALLO

The article provides a revenue breakdown for Allogene Therapeutics, Inc. (NASDAQ: ALLO) as listed on TradingView. It indicates that the market is currently closed with no trades. The content primarily outlines the financial overview, statements, statistics, dividends, earnings, and market data sources for the …

Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors

Allogene Therapeutics announced the publication of complete Phase 1 data from its TRAVERSE study of ALLO-316, an allogeneic CAR T therapy for advanced renal cell carcinoma, in the Journal of Clinical Oncology. The study showed ALLO-316 achieved a 31% confirmed response rate with the …